[1]傅洪,Victor W. Xia.术前β受体阻滞剂对肝移植术中循环管理及术后短期心肌损伤和脑卒中的影响:一项倾向评分匹配研究[J].第三军医大学学报,2019,41(23):2355-2360.
 FU Hong,Victor W. Xia.Effects of preoperative beta blockers on intraoperative circulation management and short-term myocardial injury and stroke after liver transplantation: a propensity-matched study[J].J Third Mil Med Univ,2019,41(23):2355-2360.
点击复制

术前β受体阻滞剂对肝移植术中循环管理及术后短期心肌损伤和脑卒中的影响:一项倾向评分匹配研究(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
41卷
期数:
2019年第23期
页码:
2355-2360
栏目:
临床医学
出版日期:
2019-12-15

文章信息/Info

Title:
Effects of preoperative beta blockers on intraoperative circulation management and short-term myocardial injury and stroke after liver transplantation: a propensity-matched study
作者:
傅洪Victor W. Xia
400021 重庆,重庆市急救医疗中心麻醉科1;90095-1778 美国加利福尼亚州,加州大学洛杉矶分校罗纳德里根医学中心麻醉与围术期医学科2
Author(s):
FU Hong Victor W. Xia

1Department of Anesthesiology, Chongqing Emergency Medical Center, Chongqing, 400014, China; 2Department of Anesthesiology and Perioperative Medicine, Ronald Reagan Medical Center, University of California-Los Angeles, California, 90095-1778, USA

关键词:
&beta受体阻滞剂肝移植围术期管理输血升压药再灌注后综合征心肌损伤脑卒中
Keywords:
&beta-blockers liver transplantation intraoperative management blood transfusion vasopressors post-reperfusion syndrome myocardial injury stroke
分类号:
R614.2; R619.9; R657.
文献标志码:
A
摘要:

目的采用倾向评分匹配研究方法,回顾性分析术前使用β受体阻滞剂对肝移植患者术中输血量、升压药使用、再灌注后综合征以及术后30 d内心肌损伤、脑卒中发生率的影响。方法选取加州大学洛杉矶分校罗纳德里根医学中心2005年10月至2014年9月期间接受肝移植手术的患者,按照术前是否使用β受体阻滞剂分为:β受体阻滞剂组(术前持续使用β受体阻滞剂≥7 d)643例和非β受体阻滞剂组809例。两组术前变量的差异采用单因素分析, 选取P<0.05的变量和与重要临床状态密切相关的变量进入Logistic回归方程模型,之后对两组间按照1∶1进行倾向评分匹配,比较匹配后组间在肝移植术中输血量、升压药使用情况、再灌注后综合征发生率及术后30 d内心肌损伤、脑卒中的发生率。结果2 102例患者入选本研究,单因素分析显示,使用β受体阻滞剂组患者年龄较大、男性较多,高血压、冠心病、糖尿病、胃肠道出血的发病率更高。经Logistic回归、倾向评分匹配后每组各442例患者(共884例),组间在术中输血量[(18.8±16.2)vs(20.5±18.3)U,P=0.155]、升压药使用情况(77.4% vs 79.0%,P=0.569)、再灌注后综合征发生率(14.7% vs 14.9%, P=0.901)以及术后第30天心肌损伤(3.8% vs 4.3%, P=0.761)和脑卒中(0.7% vs 2.0%, P=0.143)的发生率方面,差异均无统计学意义。结论肝移植术前使用β受体阻滞剂≥7 d不会增加术中输血量、升压药的使用以及再灌注后综合征的发生率,对术后第30天心肌损伤或缺血性脑卒中的发生率没有影响。终末期肝病患者在接受肝移植前可以继续使用β受体阻滞剂。

Abstract:

ObjectiveTo retrospectively analyze the effect of preoperative use of β-blockers on blood transfusion volume, use of pressor drugs, post-reperfusion syndrome, and incidence of heart muscle injury and stroke within 30 d after operation during liver transplantation (LT) by a propensity-matched study. MethodsA retrospective study was performed on the patients who underwent LT at UCLA Ronald Reagan medical center between October 2005 and September 2014 after the approval of the Institutional Review Board of the university (IRB#11-003058). According to the preoperative use of β-blockers or not, these patients were divided into β-blockers group (n=643) and non β-blockers group (n=809). The difference of preoperative variables between the 2 groups was analyzed by single factor analysis. The variables with a value of P<0.05 and those of important relevant clinical status were selected in a logistic regression model to generate a propensity score for each patient. The patients in 2 groups were matched in 1∶ 1 with the nearest propensity scores. The amount of blood transfusion, use of vasopressors, incidence of post-reperfusion syndrome, and occurrence of myocardial injury and stroke within 30 d after LT were compared between the 2 groups. ResultsBased on the clinical data of 2 102 patients recruited in this study, single factor analysis showed that the patients of the β-blocker group were significantly older, larger proportion of males, and higher incidences of hypertension, coronary artery disease, diabetes, and gastrointestinal bleeding. The results of logistic regression analysis eliminated after propensity match (442 patients in each group, totally 884 patients) indicated that there were no significant differences in the amount of intraoperative blood transfusion (18.8±16.1 vs 20.3±18.0 U, P=0.155), administration of vasopressors (77.4% vs 79.0%, P=0.556),  incidence of post-reperfusion syndrome (14.7% vs 14.9%, P=0.901), and occurrence of myocardial injury (3.8% vs 4.3%, P=0.761) and stroke (0.7% vs 2.0%, P=0.143) within 30 d after LT between the 2 matched groups. ConclusionPreoperative use of β-blockers for over 7 d has no effect on amount of blood transfusion, use of vasopressors, incidence of post-reperfusion syndrome, and occurrence of myocardial injury and stroke within 30 d after LT. The drug can be continuously administered for the patients with end-stage liver disease before undergoing LT.

参考文献/References:

[1]BLESSBERGER H, KAMMLER J, STEINWENDER C. Perioperative use of β-blockers in cardiac and noncardiac surgery[J]. JAMA, 2015, 313(20): 2070-2071. DOI:10.1001/jama.2015.1883.
[2]SWEDBERG K. Can beta-blockers be used safely in non-cardiac surgery? Important lessons to be learned[J]. Eur Heart J, 2017, 38(31): 2429-2430. DOI:10.1093/eurheartj/ehx291.
[3]FLEISHER L A, FLEISCHMANN K E,AUERBACH A D,et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association task force on practice guidelines[J]. J Am Coll Cardiol, 2014, 64(22): e77-e137. DOI:10.1016/j.jacc.2014.07.944.
[4]SANFILIPPO F, SANTONOCITO C, FOX P. Use of beta-blockers in non-cardiac surgery: an open debate[J]. Minerva Anestesiol, 2014, 80(4): 482-494.
[5]BOSCH J, MASTI R, KRAVETZ D, et al. Effects of propranolol on azygos venous blood flow and hepatic and systemic hemodynamics in cirrhosis[J]. Hepatology, 1984, 4(6): 1200-1205. DOI:10.1002/hep.1840040617.
[6]GARCIA-TSAO G, BOSCH J. Management of varices and variceal hemorrhage in cirrhosis[J]. N Engl J Med, 2010, 362(9): 823-832. DOI:10.1056/NEJMra0901512.
[7]QURESHI W, MITTAL C, AHMAD U, et al. Clinical predictors of post-liver transplant new-onset heart failure[J]. Liver Transpl, 2013, 19(7): 701-710. DOI:10.1002/lt.23654.
[8]SAFADI A, HOMSI M, MASKOUN W, et al. Perioperative risk predictors of cardiac outcomes in patients undergoing liver transplantation surgery[J]. Circulation, 2009, 120(13): 1189-1194. DOI:10.1161/CIRCULATIONAHA.108.847178.
[9]JUPITER D C. Propensity score matching: retrospective randomization?[J]. J Foot Ankle Surg, 2017, 56(2): 417-420. DOI:10.1053/j.jfas.2017.01.013.
[10]HAJIBANDEH S, HAJIBANDEH S, ANTONIOU S A, et al. Effect of beta-blockers on perioperative outcomes in vascular and endovascular surgery: a systematic review and meta-analysis[J]. Br J Anaesth, 2017, 118(1): 11-21. DOI:10.1093/bja/aew380.
[11]TOBIN S W, HASHEMI S, DADSON K, et al. Heart failure and MEF2 transcriptome dynamics in response to β-blockers[J]. Sci Rep, 2017, 7(1): 4476. DOI:10.1038/s41598-017-04762-x.
[12]WIJEYSUNDERA D N, DUNCAN D, NKONDE-PRICE C, et al. Perioperative beta blockade in noncardiac surgery: a systematic review for the 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association task force on practice guidelines[J]. Circulation, 2014, 130(24): 2246-2264. DOI:10.1161/CIR.00000000 00000104.
[13]AMR Y M, AMIN S M. Effects of preoperative β-blocker on blood loss and blood transfusion during spinal surgeries with sodium nitroprusside-controlled hypotension[J]. Saudi J Anaesth, 2012, 6(3): 263-267. DOI:10.4103/1658-354X.101219.
[14]SINISCALCHI A, GAMBERINI L, BARDI T, et al. Post-reperfusion syndrome during orthotopic liver transplantation, which definition best predicts postoperative graft failure and recipient mortality?[J]. J Crit Care, 2017, 41: 156-160. DOI:10.1016/j.jcrc.2017.05.020.
[15]KORK F, RIMEK A, ANDERT A, et al. Visual quality assessment of the liver graft by the transplanting surgeon predicts postreperfusion syndrome after liver transplantation: a retrospective cohort study[J]. BMC Anesthesiol, 2018, 18(1): 29. DOI:10.1186/s12871-018-0493-9.
[16]FORD R M, BOOK W, SPIVEY J R. Liver disease related to the heart[J]. Transplant Rev (Orlando), 2015, 29(1): 33-37. DOI:10.1016/j.trre.2014.11.003.
[17]ZARDI E M, ZARDI D M, CHIN D, et al. Cirrhotic cardiomyopathy in the pre- and post-liver transplantation phase[J]. J Cardiol, 2016, 67(2): 125-130. DOI:10.1016/j.jjcc.2015.04.016.
[18]NICOLAU-RADUCU R, GITMAN M, GANIER D, et al. Adverse cardiac events after orthotopic liver transplantation: a cross-sectional study in 389 consecutive patients[J]. Liver Transpl, 2015, 21(1): 13-21. DOI:10.1002/lt.23997.
[19]WESSELINK E M, KAPPEN T H, TORN H M, et al. Intraoperative hypotension and the risk of postoperative adverse outcomes: a systematic review[J]. Br J Anaesth, 2018, 121(4): 706-721. DOI:10.1016/j.bja.2018.04.036.
[20]WIJEYSUNDERA D N, BEATTIE W S, WIJEYSUNDERA H C, et al. Duration of preoperative β-blockade and outcomes after major elective noncardiac surgery[J]. Can J Cardiol, 2014, 30(2): 217-223. DOI:10.1016/j.cjca.2013.10.011.
[21]FLU W J, VAN KUIJK J P, CHONCHOL M, et al. Timing of pre-operative Beta-blocker treatment in vascular surgery patients: influence on post-operative outcome[J]. J Am Coll Cardiol, 2010, 56(23): 1922-1929. DOI:10.1016/j.jacc.2010.05.056.
[22]SERST T, FRANCOZ C, DURAND F, et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study[J]. J Hepatol, 2011, 55(4): 794-799. DOI:10.1016/j.jhep.2011.01.034.
[23]GE P S, RUNYON B A. When should the β-blocker window in cirrhosis close?[J]. Gastroenterology, 2014, 146(7): 1597-1599. DOI:10.1053/j.gastro.2014.04.028.
[24]AUSTIN P C, MAMDANI M M, STUKEL T A, et al. The use of the propensity score for estimating treatment effects: administrative versus clinical data[J]. Stat Med, 2005, 24(10): 1563-1578. DOI:10.1002/sim.2053.
[25]AUSTIN P C, GROOTENDORST P, ANDERSON G M. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study[J]. Stat Med, 2007, 26(4): 734-753. DOI:10.1002/sim.2580.

更新日期/Last Update: 2019-12-09